FORTIS902.00

Fortis Healthcare Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAPOLLOHOSPMAXHEALTHMEDANTAAUROPHARMALUPINALKEMLAURUSLABSMANKINDMcap ₹68,097 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations1,770.01,679.71,785.91,858.91,988.41,928.32,007.22,166.72,331.42,265.02,364.72,545.0
Other Income13.56.89.813.013.220.919.815.422.68.34.414.5
Total Income1,783.51,686.51,795.71,871.92,001.61,949.22,027.02,182.12,354.02,273.32,369.12,559.5
Expenses
+ Purchases of Stock-in-Trade416.2388.8402.6455.3465.8457.4459.6517.9547.8522.2520.7585.6
+ Changes in Inventories-3.55.011.1-2.5-4.9-3.93.4-3.8-8.3-6.1-1.9-12.6
+ Employee Benefit Expense281.4282.1271.5295.4290.3294.2287.3312.8316.6327.6339.7404.4
+ Finance Costs31.833.034.735.336.445.267.669.674.985.784.380.4
+ Depreciation & Amortisation84.186.992.291.095.197.3102.2101.5105.8120.1122.0121.9
+ Other Expenses745.7719.9719.6768.1802.4805.4821.4849.2918.9915.6973.81,030.6
Total Expenses1,555.71,515.61,531.81,642.71,685.01,695.61,741.51,847.11,955.81,965.22,038.62,210.2
EBITDA330.2284.0381.0342.5434.8375.1435.5490.7556.3505.7532.3537.1
EBIT246.1197.1288.8251.5339.8277.8333.2389.2450.5385.5410.4415.2
Profit
PBT before Exceptional Items227.7170.9263.9229.3316.6253.5285.5335.0398.2308.1330.5349.3
+ Exceptional Items3.77.73.10.2-59.823.8-53.612.623.5-45.9-12.59.5
Pretax Income231.4178.6267.1229.5256.8277.3231.9347.7421.7262.2318.0358.8
+ Current Tax48.838.876.151.751.544.734.439.948.054.965.686.2
+ Deferred Tax0.010.1-7.94.416.4-19.614.143.948.613.4-12.64.2
Tax Expense48.848.968.256.168.025.148.583.896.668.353.090.4
+ Share of Associates & JVs1.34.54.30.64.22.14.62.93.73.56.24.4
Net Income183.9134.2203.1174.0193.1254.3188.0266.8328.8197.4271.2272.8
+ Net Income — Continuing Ops182.6129.7198.8173.4188.9252.2183.4263.9325.1193.9265.0268.4
+ Other Comprehensive Income-0.70.10.1-0.3-0.60.5-3.0-0.56.34.52.30.1
Total Comprehensive Income183.3134.3203.2173.7192.5254.8185.0266.3335.1201.9273.5272.9
Net Income to Common173.7134.7178.7165.8175.9247.9183.9260.3321.9193.7265.9266.4
Minority Interest10.2-0.424.47.916.66.44.16.56.93.75.36.4
Per Share
Basic EPS2.301.782.372.202.343.282.443.454.262.573.523.53
Diluted EPS2.301.782.372.202.343.282.443.454.262.573.523.53
Other Comprehensive Income — detail
+ Other Comprehensive Income-3.0-0.56.34.52.30.1
+ Items NOT to be Reclassified to P&L0.3-0.4-0.3-0.3-1.8-0.3-5.6-3.13.52.0-3.4-0.4
+ Tax on Items NOT to be Reclassified-1.7-0.70.60.5-0.6-0.1
+ Tax on Items NOT to be Reclassified — alt tag-0.3-0.10.0-0.1-0.2-0.0
+ Items to be Reclassified to P&L0.40.4-0.11.00.70.91.93.05.10.4
+ Tax on Items to be Reclassified0.00.0-3.40.00.00.0
+ Tax on Items to be Reclassified — alt tag1.20.00.00.00.00.0
Comprehensive Income — Owners of Parent173.4134.90.1-0.2-0.6248.5-3.0259.9328.1198.4268.2266.5
Comprehensive Income — Non-controlling Interests9.9-0.6-0.1-0.10.06.3-0.16.47.03.55.46.4
Per Share — as-filed variants
Basic EPS — Continuing Operations2.301.782.372.202.343.282.443.454.262.573.523.53
Diluted EPS — Continuing Operations2.301.782.372.202.343.282.443.454.262.573.523.53
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,357.21,285.91,372.21,406.01,527.61,474.81,544.21,652.61,791.91,748.91,845.81,972.1
Gross Margin %76.6876.5676.8475.6476.8276.4876.9376.2776.8677.2178.0677.49
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)227.7170.9263.9229.3316.6253.5285.5335.0398.2308.1330.5349.3
− Exceptional Items (reconciliation)3.77.73.10.2-59.823.8-53.612.623.5-45.9-12.59.5
Net Income Adj (tax-effected)181.0128.6200.8173.8237.0232.7230.4257.2310.7231.4281.6265.7
EPS Adj2.261.712.342.202.873.002.993.334.023.013.663.44
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Filed Debt Equity0.000.000.000.000.000.000.00
Filed Dscr0.030.080.060.020.020.010.01
Filed Iscr0.090.070.070.080.060.060.07
Paid Up Equity Capital755.0755.0755.0755.0755.0755.0755.0755.0755.0755.0755.0755.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.